[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[S. 4120 Engrossed in Senate (ES)]
<DOC>
117th CONGRESS
2d Session
S. 4120
_______________________________________________________________________
AN ACT
To maximize discovery, and accelerate development and availability, of
promising childhood cancer treatments, and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Childhood Cancer Survivorship,
Treatment, Access, and Research Reauthorization Act of 2022'' or the
``Childhood Cancer STAR Reauthorization Act''.
SEC. 2. REAUTHORIZING AND IMPROVING THE CHILDHOOD STAR ACT.
(a) Children's Cancer Biorepositories.--Section 417E of the Public
Health Service Act (42 U.S.C. 285a-11) is amended--
(1) in subsection (a)--
(A) in paragraph (2)(A), by inserting before the
period at the end of the second sentence the following:
``, such as collected samples of both solid tumor
cancer and paired samples'';
(B) in paragraph (9), by striking ``Childhood
Cancer Survivorship, Treatment, Access, and Research
Act of 2018'' and inserting ``Childhood Cancer
Survivorship, Treatment, Access, and Research
Reauthorization Act of 2022'';
(C) by redesignating paragraph (10) as paragraph
(11); and
(D) by inserting after paragraph (9) the following:
``(10) Report on researcher access to children's cancer
biorepository samples.--Not later than 2 years after the date
of enactment of the Childhood Cancer Survivorship, Treatment,
Access, and Research Reauthorization Act of 2022, the Director
of NIH shall--
``(A) conduct a review of the procedures
established under paragraph (2)(C) and other policies
or procedures related to researcher access to such
biospecimens to identify any opportunities to reduce
administrative burden, consistent with paragraph
(2)(D), in a manner that protects personal privacy to
the extent required by applicable Federal and State
privacy law, at a minimum; and
``(B) submit to the Committee on Health, Education,
Labor, and Pensions of the Senate and the Committee on
Energy and Commerce of the House of Representatives a
report on the findings of the review under subparagraph
(A) and whether the Director of NIH plans to make any
changes to the policies or procedures considered in
such review, based on such findings.''; and
(2) in subsection (d), by striking ``2019 through 2023''
and inserting ``2024 through 2028''.
(b) Cancer Survivorship Programs.--Section 201 of the Childhood
Cancer Survivorship, Treatment, Access, and Research Act of 2018
(Public Law 115-180) is amended--
(1) in subsection (a)--
(A) in the subsection heading, by striking ``Pilot
Programs to Explore'' and inserting ``Research to
Evaluate''
(B) in paragraph (1)--
(i) by striking ``may make awards to
eligible entities to establish pilot programs''
and inserting ``shall, as appropriate, make
awards to eligible entities to conduct or
support research'';
(ii) by striking ``model systems'' and
inserting ``approaches'';
(iii) by inserting ``and adolescent'' after
``childhood''; and
(iv) by striking ``evaluation of models
for'';
(C) in paragraph (2)--
(i) in subparagraph (A), in the matter
preceding clause (i), by inserting ``within the
existing peer review process,'' after
``practicable,''; and
(ii) in subparagraph (B)(v), by striking
``in treating survivors of childhood cancers''
and inserting ``in carrying out the activities
described in paragraph (1)''; and
(D) in paragraph (3)(B)(v), by striking ``design of
systems for the effective transfer of treatment
information and care summaries from cancer care
providers to other health care providers'' and
inserting ``design tools to support the secure
electronic transfer of treatment information and care
summaries between health care providers or, as
applicable and appropriate, longitudinal childhood
cancer survivorship cohorts''; and
(2) in subsection (b)--
(A) in each of paragraphs (1) and (2), by striking
``date of enactment of this Act'' and inserting ``date
of enactment of the Childhood Cancer Survivorship,
Treatment, Access, and Research Reauthorization Act of
2022''; and
(B) in paragraph (1)--
(i) by striking subparagraphs (A) and (C);
(ii) by redesignating subparagraph (B) as
subparagraph (A); and
(iii) by adding at the end the following:
``(B) recommendations for enhancing or promoting
activities of the Department of Health and Human
Services related to workforce development for health
care providers who provide psychosocial care to
pediatric cancer patients and survivors.''.
Passed the Senate December 20, 2022.
Attest:
Secretary.
117th CONGRESS
2d Session
S. 4120
_______________________________________________________________________
AN ACT
To maximize discovery, and accelerate development and availability, of
promising childhood cancer treatments, and for other purposes.